AARP Maryland Applauds Launch of Longevity Ready Maryland
ANNAPOLIS, Md., July 30, 2025 /PRNewswire/ — AARP Maryland is welcoming the launch of Longevity Ready Maryland, a comprehensive, 10-year multisector plan to coordinate services and policies that support Maryland's growing population of older adults.
'With more than 850,000 AARP members across Maryland, we know firsthand the urgency of preparing for a future where older adults make up a growing share of our population. Longevity Ready Maryland is a forward-thinking, inclusive strategy that recognizes the vital role of collaboration across sectors,' said AARP Maryland State Director Hank Greenberg. 'By aligning resources and strengthening community-based supports, this plan lays the foundation for a Maryland where every older adult can age with dignity, independence, and purpose.'
The launch of Longevity Ready Maryland comes on the heels of a recent report by the U.S. Census Bureau that the number of Marylanders age 65 and older grew by 3.35% from 2023 to 2024, while the number of those under age 18 fell by 0.06%.
For additional information about Longevity Ready Maryland visit:
Main Website: LRM.Maryland.Gov
Full Plan Download: Click here to download the complete plan
Data Dashboard: Explore the data here
About AARP
AARP is the nation's largest nonprofit, nonpartisan organization dedicated to empowering Americans 50 and older to choose how they live as they age. With a nationwide presence, AARP strengthens communities and advocates for what matters most to the more than 100 million Americans 50-plus and their families: health security, financial stability and personal fulfillment. AARP also works for individuals in the marketplace by sparking new solutions and allowing carefully chosen, high-quality products and services to carry the AARP name. As a trusted source for news and information, AARP produces the nation's largest circulation publications, AARP The Magazine and AARP Bulletin. To learn more, visit www.aarp.org/about-aarp/, www.aarp.org/español or follow @AARP, @AARPenEspañol and @AARPadvocates on social media.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
3 days ago
- Malaysian Reserve
Elixir MD Launches Australia & New Zealand Subsidiary in Exclusive Partnership with High Tech Medical Pty. Ltd.
IRVINE, Calif. and QUEENSLAND, Australia, Aug. 1, 2025 /PRNewswire/ — ELIXIR MD, Inc., a pioneer in advanced medical technology and proprietary treatment protocols for plastic surgery, today announced the formation of its wholly owned subsidiary in Australia and New Zealand, alongside an exclusive partnership with High Tech Medical Pty Ltd. to launch the ELIXIR MD™ device across the region. Ewan Mohammed, CEO of ELIXIR MD, Inc., stated:'We're proud to join forces with High Tech Medical—Australia and New Zealand's leading medical technology partner—to bring the ELIXIR MD™ device to facial surgery patients across one of the world's fastest-growing cosmetic markets. With more than 25 years of proven commitment to clinical excellence, High Tech Medical brings deep market insight and trusted relationships throughout the aesthetic medical community. Their long-standing success in introducing advanced technologies to Australians and New Zealanders makes them the ideal partner for ELIXIR MD, Inc.' Matt Moncrieff, Managing Director of High-Tech Medical Pty Ltd., added:'High Tech Medical is proud to work exclusively with ELIXIR MD, Inc., Ewan and the entire team have demonstrated a clear commitment to innovation and to reshaping the perioperative care model in plastic surgery. The ELIXIR MD™ device and its proprietary treatment protocols represent a new gold standard in post-surgical recovery by significantly reducing patient downtime and improving outcomes.' Australia and New Zealand: A Rising Market for Surgical Innovation Australian cosmetic surgery market reached approximately $1.8B in 2024, with expected growth to $3.9B by 2033, reflecting a CAGR of ~9.3% (IMARC Group, Rentech Digital). Facial cosmetic surgery—the category where ELIXIR MD™ is uniquely focused—is the fastest-growing segment of the cosmetic surgery market in Australia, with a projected CAGR of approximately 14.1% through 2030 (Grand View Research). Demand for face and eyelid surgeries (e.g. blepharoplasty, facelifts) is rising sharply in Australia and New Zealand, in key part driven by post-weight loss volume depletion and rejuvenation surgery (Daily Telegraph). About High Tech Medical Pty in 1999, High Tech Medical is one of the most respected providers of specialist aesthetic medical devices across Australia and New Zealand. With over two decades of leadership, the company has introduced breakthrough technologies that support minimally invasive treatments, reduce patient risk and downtime, and improve clinical outcomes. High Tech Medical is known for its consultative approach—helping practitioners select and integrate complex, high-performance systems into their practices with confidence. About ELIXIR MD, in Irvine, California, ELIXIR MD, Inc. is a medical technology company redefining recovery in plastic surgery through non-invasive, perioperative innovations. Now operating in 18 markets—including a wholly owned subsidiary in Australia and New Zealand—our FDA-cleared ELIXIR MD™ technology is built to support faster healing and better outcomes for surgeons and their patients worldwide.
New Straits Times
3 days ago
- New Straits Times
#SHOWBIZ: Justin Timberlake reveals battle with 'relentlessly debilitating' Lyme disease
NEW YORK CITY: Justin Timberlake has disclosed that he was diagnosed with Lyme disease, describing it as "relentlessly debilitating." The singer made the candid revelation in an Instagram post after the final show of his Forget Tomorrow tour in Turkey. The 44-year-old artiste said he had been silently dealing with health issues throughout the tour. "I've been battling some health issues and was diagnosed with Lyme disease. I'm sharing this to shed light on what I've been up against, and not for sympathy," he wrote. Lyme disease is a bacterial infection spread by tick bites that can cause symptoms such as nerve pain, extreme fatigue, and cognitive difficulties. Timberlake said the diagnosis explained the nerve pain and exhaustion he experienced while performing. Despite the challenges, the *NSYNC alum chose to continue with the tour. "The joy that performing brings me far outweighs the fleeting stress my body was feeling. I'm so glad I kept going," he said. Timberlake added that he chose to go public to avoid misunderstandings and to demonstrate his resilience. "I wanted to be transparent, so my struggles wouldn't be misinterpreted. I'm proud of my mental tenacity," he explained. The tour, which began in April 2024, spanned Europe, North America, and Asia. It received mixed reviews, with some critics noting underwhelming performances, which now make more sense in light of his health battle. Timberlake, who has sold over 88 million records and won ten Grammy Awards, is married to actress Jessica Biel, 42. They share two sons, Silas and Phineas. He joins other celebrities like Avril Lavigne and Bella Hadid who have also spoken out about their experiences with Lyme disease. The US public health agency, the Centers for Disease Control and Prevention, estimates that the illness affects nearly half a million Americans each year.
Malaysian Reserve
3 days ago
- Malaysian Reserve
ASPIRE for Lung Cancer launches the APAC Lung Cancer Policy Consensus as a regional call to action for improved lung cancer care
SINGAPORE, Aug. 1, 2025 /PRNewswire/ — On 31st July 2025, a unified consensus document for improving lung cancer care in the Asia-Pacific (APAC) region was officially launched in Singapore, marking a pivotal moment in the regional fight against lung cancer. This represents the first comprehensive consensus for the region, an evidence-based agreement between stakeholders across the healthcare ecosystem that outlines shared priorities, strategies, and recommendations to elevate the standard of lung cancer care across diverse health systems. Held on the eve of World Lung Cancer Day, the initiative involved over 43 contributors, including clinicians, academics, patient advocates, and health organisations across 14 APAC health systems. Launch Highlights and Key Voices The APAC Lung Cancer Policy Consensus was launched with keynote contributions from: Dr Mary Bussell (TriMar Strategies), who delivered an overview of the global lung cancer consensus and its relevance to regional efforts Mr Yannick Romero (Union for International Cancer Control – UICC), who contextualised the APAC consensus within the broader global lung health resolution, emphasising policy alignment and strategic integration Ms Helena Wilcox (The Lung Cancer Policy Network – LCPN), who highlighted how the APAC framework enables regional advancement in care and partnership building Mr Francis Goh (Lung Cancer Education and Advocacy for Patients – LEAP), Singapore) stressed the pivotal role of patient voices in shaping lung cancer policy and health system transformation A/Prof Herbert Loong (Asia Pacific Coalition against Lung Cancer – APCLC) and Asst Prof Yeon Wook Kim (SNU Bundang Hospital), who provided an in-depth presentation on the consensus development process, five key pillars, and concrete calls to action Lung cancer remains the leading cause of cancer-related deaths in the APAC region, and accounts for nearly 60% of global cases. With regional incidence projected to exceed 1.8 million by 2040, the need for a cohesive, regional strategy to combat the disease has never been more urgent. Furthermore, survival rates in the APAC region often lag behind global benchmarks, with five-year survival rates frequently below 20%. This fragmented landscape highlights the critical need for a coordinated approach, one that addresses the unique epidemiological, environmental, and healthcare challenges within the region. The APAC Lung Cancer Policy Consensus is the result of an extensive collaborative process involving two expert working sessions, one patient workshop and a final expert voting session, with input from patients, clinicians and academic leaders across the region. The consensus lays out a unified policy framework anchored in five core principles, all aimed at driving sustainable, equitable improvements in lung cancer prevention, detection, treatment, and stigma reduction across the region. Importantly, the APAC Consensus aligns closely with the Global Lung Cancer Consensus, which was first ratified at the 9th International Lung Cancer Network in 2023. By endorsing this global statement, the APAC region reaffirms its commitment to improving lung cancer outcomes. The Five Global Principles Anchoring the APAC Lung Cancer Policy Consensus: Improve and Expand Prevention Strengthen tobacco control, public education, and environmental risk research to prevent lung cancer across all exposure types Expand screening and diagnostic access through inclusive guidelines and innovative technologies to enable timely lung cancer detection Promote timely, affordable access to modern and personalised lung cancer treatments across diverse healthcare settings Foster cross-sectoral collaboration and advocacy to drive investment and policy reform in lung cancer care Address stigma through education and empowerment to support early diagnosis, treatment adherence, and community acceptance A Region-Specific Approach to Lung Cancer Care The APAC Lung Cancer Policy Consensus is not just a regional adaptation of global recommendations; it is a comprehensive response to the distinct challenges faced by the APAC region. Unlike Western health systems that primarily focus on smoking-related lung cancer, the APAC region must contend with a higher prevalence of lung cancer in never-smokers due to factors such as environmental pollutants, and genetic predispositions. Moreover, the region's healthcare systems are highly heterogeneous, ranging from well-resourced settings with cutting-edge cancer care to lower-resource environments building on basic cancer services. Given these disparities, a one-size-fits-all approach would be ineffective. The APAC Lung Cancer Policy Consensus presents a regionally tailored action plan that offers specific strategies and targets to improve lung cancer care and outcomes, ensuring that every health system in the region, regardless of its capacity, can make progress toward the shared goals. 'We call on policymakers, healthcare leaders, and stakeholders across the APAC region to urgently prioritise and implement policies that improve lung cancer outcomes. While the specific solutions will vary across health systems, this consensus provides a shared foundation to guide national efforts. By acting now and adapting these recommendations to local contexts, we can foster a future where healthcare systems of all sizes work together to overcome regional challenges.' said Judy Li, Consortium Manager at ASPIRE for Lung Cancer. Looking Ahead The launch of the APAC Lung Cancer Policy Consensus marks the start of a sustained regional effort to transform lung cancer care in the Asia-Pacific region. Over the coming months, ASPIRE for Lung Cancer and its partners will continue to engage with policymakers, healthcare leaders, and patient advocacy groups to ensure that the consensus principles are translated into concrete action, with measurable outcomes. Through this regional collaboration, APAC aims to drive meaningful change that will improve survival rates and quality of life for lung cancer patients across the region. For more details about the APAC Lung Cancer Policy Consensus or to learn how you can get involved in advancing lung cancer care in your region, visit About ASPIRE for Lung Cancer ASPIRE (Asia Pacific Policy Review and Engagement) for Lung Cancer is a collaborative multilateral effort focused on improving lung cancer outcomes in the Asia-Pacific region through policy reforms. We advocate for prioritising lung cancer in government action plans, aiming to drive transformative changes that enhance patient access and care. We believe in the influence of collaboration and collective action to drive positive change. We therefore work with governments, agencies, NGOs and patient groups, bringing together multi-disciplinary experts to improve health outcomes for lung cancer patients in the APAC region. CONTACT: ASPIRE for Lung Cancer,
